Mitsubishi UFJ Asset Management
RARE icon

Mitsubishi UFJ Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$348K Buy
10,437
+2,823
+37% +$70.1K ﹤0.01% 939
2026
Q1 		$160K Sell
7,614
-177
-2% -$3.99K ﹤0.01% 1010
2025
Q4 		$184K Buy
7,791
+996
+15% +$32.8K ﹤0.01% 1032
2025
Q3 		$204K Buy
6,795
+12
+0.2% +$360 ﹤0.01% 992
2025
Q2 		$247K Buy
6,783
+441
+7% +$15.9K ﹤0.01% 953
2025
Q1 		$230K Buy
6,342
+493
+8% +$20.5K ﹤0.01% 943
2024
Q4 		$243K Sell
5,849
-712
-11% -$35.3K ﹤0.01% 963
2024
Q3 		$364K Sell
6,561
-613
-9% -$31.2K ﹤0.01% 895
2024
Q2 		$295K Buy
7,174
+1,123
+19% +$48K ﹤0.01% 920
2024
Q1 		$283K Sell
6,051
-274
-4% -$12.9K ﹤0.01% 923
2023
Q4 		$303K Buy
6,325
+757
+14% +$29.3K ﹤0.01% 971
2023
Q3 		$198K Buy
5,568
+79
+1% +$3.13K ﹤0.01% 1023
2023
Q2 		$253K Sell
5,489
-2,328
-30% -$108K ﹤0.01% 1007
2023
Q1 		$313K Buy
7,817
+468
+6% +$20.1K ﹤0.01% 977
2022
Q4 		$335K Buy
7,349
+2,061
+39% +$81.1K ﹤0.01% 971
2022
Q3 		$219K Buy
5,288
+9
+0.2% +$462 ﹤0.01% 1013
2022
Q2 		$315K Buy
5,279
+1,387
+36% +$85.3K ﹤0.01% 990
2022
Q1 		$283K Buy
3,892
+225
+6% +$15.7K ﹤0.01% 1005
2021
Q4 		$309K Buy
3,667
+922
+34% +$75K ﹤0.01% 1003
2021
Q3 		$248K Hold
2,745
– – ﹤0.01% 1030
2021
Q2 		$262K Sell
2,745
-435
-14% -$45.3K ﹤0.01% 1055
2021
Q1 		$362K Buy
3,180
+1,068
+51% +$145K ﹤0.01% 931
2020
Q4 		$292K Sell
2,112
-586
-22% -$69.5K ﹤0.01% 913
2020
Q3 		$222K Buy
2,698
+38
+1% +$3.15K ﹤0.01% 887
2020
Q2 		$208K Sell
2,660
-2,014
-43% -$133K ﹤0.01% 889
2020
Q1 		$208K Buy
4,674
+835
+22% +$43.4K ﹤0.01% 848
2019
Q4 		$165K Buy
3,839
+1,309
+52% +$54K ﹤0.01% 903
2019
Q3 		$108K Buy
2,530
+503
+25% +$27.3K ﹤0.01% 896
2019
Q2 		$129K Sell
2,027
-276
-12% -$17.6K ﹤0.01% 891
2019
Q1 		$160K Buy
2,303
+379
+20% +$21.7K ﹤0.01% 821
2018
Q4 		$77K Buy
1,924
+274
+17% +$15K ﹤0.01% 878
2018
Q3 		$126K Buy
+1,650
New +$134K ﹤0.01% 826

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Mitsubishi UFJ Asset Management's RARE Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management increased its Ultragenyx Pharmaceutical (RARE) stake by 37% in Q2 2026, buying an estimated $70.1K and bringing the position to 10,437 shares worth $348K. The position accounts for ﹤0.01% of the portfolio, ranked #939.

Mitsubishi UFJ Asset Management first reported a position in RARE in Q3 2018 and has held it in 32 quarters since. The position peaked at $364K in Q3 2024. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Mitsubishi UFJ Asset Management held 10,437 shares of Ultragenyx Pharmaceutical worth $348K as of Q2 2026.
  • Mitsubishi UFJ Asset Management bought 2,823 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $70.1K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Mitsubishi UFJ Asset Management's portfolio in Q2 2026, its #939 holding.
  • Mitsubishi UFJ Asset Management first reported a position in Ultragenyx Pharmaceutical in Q3 2018 and has held it in 32 quarters since.
  • Mitsubishi UFJ Asset Management's Ultragenyx Pharmaceutical position peaked at $364K in Q3 2024.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.